ETON
Eton Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$49.22
−2.17%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$50.22
From 52W high−23.61%
Volume368207.00
Market cap$1.41B
P/E (TTM)105.8x
P/S (TTM)13.3x
Div yield—
Key dataOct 19, 2026
Open
$50.22
From 52W high
−23.61%
Volume
368207.00
Market cap
$1.41B
ValuationView details →
P/E (Fwd)
30.7x
EV/EBITDA
70.6x
P/E (TTM)
105.8x
RSI (14)
35.1
MomentumView details →
1D Return
−2.17%
YTD Return
+191.90%
SummaryUpdated Jun 1, 2026
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) is a specialty pharmaceutical company founded in 2017 and based in Deer Park, Illinois. The company went public in November 2018 and focuses on developing and commercializing pharmaceutical products for rare diseases, particularly those affecting fewer than 10,000 patients in the United States. Since its inception, Eton has transformed from a development-stage company into a commercial enterprise with multiple approved products, achieving consistent revenue growth and reaching near-profitability by 2024.
Similar companies
Latest newsMore news →
Aquestive Therapeutics agreed to serve as Eton Pharmaceuticals' exclusive manufacturer and supplier of the product under a supply agreement with an initial 20-year term.6d agoEton Pharmaceuticals, Inc. and Aquestive Therapeutics, Inc. announced an exclusive U.S. licensing and supply agreement for LIBERVANT (diazepam) buccal film.6d agoEton Pharmaceuticals launched IMPAVIDO (miltefosine) capsules in the United States.22d ago